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ABSTRACT 1 
We have analyzed the cellular pathways and metabolic adaptations that take place in 2 
primary skin fibroblasts from patients with mutations in BCS1L, a major genetic cause 3 
of mitochondrial complex III enzyme deficiency. Mutant fibroblasts exhibited low 4 
oxygen consumption rates and intracellular ATP levels, indicating that the main altered 5 
molecular event probably is a limited respiration-coupled ATP production through the 6 
OXPHOS system. Two-dimensional DIGE and MALDI-TOF/TOF mass spectrometry 7 
analyses unambiguously identified 39 proteins whose expression was significantly 8 
altered in complex III-deficient fibroblasts. Extensive statistical and cluster analyses 9 
revealed a protein profile characteristic for the BCS1L mutant fibroblasts that included 10 
alterations in energy metabolism, cell signaling and gene expression regulation, 11 
cytoskeleton formation and maintenance, and intracellular stress responses. The 12 
physiological validation of the predicted functional adaptations of human cultured 13 
fibroblasts to complex III deficiency confirmed the up-regulation of glycolytic enzyme 14 
activities and the accumulation of branched-chain among other amino acids, suggesting 15 
the activation of anaerobic glycolysis and cellular catabolic states, in particular protein 16 
catabolism, together with autophagy as adaptive responses to mitochondrial respiratory 17 
chain dysfunction and ATP deficiency. Our data point to an overall metabolic and 18 
genetic reprogramming that could contribute to explain the clinical manifestations of 19 
complex III deficiency in patients. 20 
21 
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BIOLOGICAL SIGNIFICANCE 1 
Despite considerable knowledge about their genetic origins, the 2 
pathophysiological mechanisms that contribute to the clinical manifestations of 3 
mitochondrial disorders remain poorly understood. We have investigated the molecular 4 
pathways and metabolic adaptations that take place in primary skin fibroblasts from 5 
patients with mutations in the BCS1L gene, a primary cause of mitochondrial complex 6 
III enzyme deficiency. Two-dimensional DIGE together with MALDI-TOF/TOF mass 7 
spectrometry and physiological validation analyses revealed a significant metabolic and 8 
genetic reprogramming as an adaptive response to mitochondrial respiratory chain 9 
dysfunction. Our data provide information about specific protein targets that regulate 10 
the transmitochondrial functional responses to complex III deficiency, thereby opening 11 
new doors for future research. 12 
13 
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INTRODUCTION 1 
Mitochondria participate as key regulators of cellular metabolism in a large 2 
variety of physiological processes, and provide most of the cellular energy (ATP) 3 
through the oxidative phosphorylation (OXPHOS) system. The OXPHOS system is 4 
located in the mitochondrial inner membrane and it is formed by five multiprotein 5 
enzyme complexes that couple respiration and ATP synthesis. Among these, respiratory 6 
chain cytochrome bc1 complex (or complex III) catalyzes the transfer of electrons from 7 
reduced coenzyme Q to cytochrome c associated with proton pumping to the 8 
intermembrane space [1]. The purified bovine complex is a ~450 kDa symmetric 9 
homodimer [2, 3]. Each monomer is composed of three catalytic subunits (cytochrome 10 
b, cytochrome c1 and the Rieske Iron-Sulfur Protein, or RISP) and eight structural 11 
subunits of unknown function.  12 
Isolated complex III enzyme deficiencies cause a broad spectrum of symptoms 13 
that display tissue specificity in humans [4]. They are caused by mutations in catalytic 14 
and structural subunits as well as in assembly factors [5-10]. So far, the vast majority of 15 
mutations leading to complex III deficiency have been localized to the nuclear BCS1L 16 
gene, which encodes a mitochondrial inner membrane translocase necessary for the 17 
import and insertion of the RISP subunit into complex III [11]. BCS1L mutations lead to 18 
three main clinical phenotypes [12]: (1) Björnstad Syndrome, an autosomal recessive 19 
disorder characterized by sensorineural hearing loss and pili torti [13]; (2) GRACILE 20 
Syndrome, a Finnish-heritage disease caused by the homozygous p.Ser78Gly mutation 21 
[14], which is characterized by fetal growth retardation, aminoaciduria, cholestasis, iron 22 
overload, lactic acidosis, and early death; and (3) Complex III deficiency in neonates, 23 
infants or adults presenting with liver disease and lactic acidosis, alone or in 24 
combination with encephalopathy and visceral involvement [6, 15-21].  25 
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The pathophysiological mechanisms that contribute to the clinical manifestations 1 
of BCS1L mutations remain poorly understood. Mutations in BCS1L may lead to 2 
mitochondrial complex III assembly and enzyme defects in patients with Björnstad 3 
Syndrome or complex III deficiency [13, 17, 22], as well as in late stages of GRACILE 4 
Syndrome in Bcs1l transgenic mice [23]. This has been proposed to increase oxidative 5 
stress through the production of reactive oxygen species (ROS) in a mutation-dependent 6 
manner [13, 22]. A study from our group established a correlation between the severity 7 
of the clinical manifestations of complex III deficiency and specific cellular 8 
pathophysiological parameters in skin fibroblasts from six patients harboring mutations 9 
in the BCS1L gene [22]. Cells from patients with the most severe clinical phenotypes 10 
exhibited the slowest growth rates in glucose medium, displayed severe enzyme 11 
deficiencies and assembly defects of the respiratory chain complexes, increased ROS 12 
levels and unbalanced expression of the cellular antioxidant defenses, fragmented 13 
mitochondrial networks and increased cell death rates [22]. In agreement, BCS1L 14 
knockdown in human cells caused the disassembly of the mitochondrial 15 
supercomplexes and led to morphological alterations of the mitochondrial network [24]. 16 
On the contrary, Finnish patients with GRACILE syndrome exhibited normal complex 17 
III activity [14], and the fact that BCS1L functions as a mitochondrial translocase 18 
suggests that this protein could have broader functional implications than complex III 19 
assembly. Iron overload is also a common feature of patients with BCS1L mutations 20 
leading to GRACILE syndrome or complex III deficiency, which suggests an additional 21 
hypothetical role for BCS1L in iron metabolism [14, 16, 25].  22 
To further identify the mechanisms underlying complex III deficiency, we have 23 
undertaken a combination of functional studies and high-resolution differential 24 
proteomics in cultured skin fibroblasts from four complex III-deficient patients 25 
harboring mutations in the BCS1L gene and four healthy controls. Mutant fibroblasts 26 
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showed significantly lower oxygen consumption rates and intracellular ATP levels than 1 
controls. Subsequent two-dimensional differential gel electrophoresis (2D-DIGE) and 2 
MALDI-TOF/TOF mass spectrometry analyses revealed a protein profile characteristic 3 
for the BCS1L mutant fibroblasts that involved alterations in the energy metabolism, 4 
cytoskeleton formation and maintenance, regulation of gene and protein expression, cell 5 
signaling and the cellular stress responses. Physiological validation analyses suggested 6 
the activation of anaerobic glycolysis, cellular catabolism and autophagy as main 7 
adaptive responses to mitochondrial respiratory chain dysfunction and ATP deficiency. 8 
These data represent novel starting points for elucidating the molecular mechanisms of 9 
complex III deficiency. 10 
 11 
12 
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MATERIAL AND METHODS 1 
Fibroblast cultures  2 
Primary skin fibroblasts from four patients and four healthy donors (age and sex-3 
matched) were cultured in 1 g/l glucose-containing Dulbecco´s modified Eagle´s 4 
Medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (FBS), 100 5 
IU/ml penicillin and 100 IU/ml streptomycin at 37ºC and 5% CO2. Mycoplasma testing 6 
was performed in fibroblasts by DAPI staining and epifluorescence microscopy, which 7 
yielded negative results. Control and patients´ cells were balanced for passage number 8 
(9-10 passages). 9 
Cell respiration 10 
Oxygen consumption in human fibroblasts was measured using an XF24 11 
Extracellular Flux Analyzer (Seahorse Bioscience). To obtain a homogeneous 12 
monolayer of cells, around 5.0 ×104 cells per well were plated the day before the 13 
experiment, depending on the growth rate of each cell line, and in order to obtain about 14 
15 µg protein per well on the day of the experiment. The cells were then incubated for 1 15 
h in unbuffered DMEM supplemented with 1 g/l glucose, 1 mM sodium pyruvate and 2 16 
mM glutamine at 37ºC in a CO2-free incubator. In all experiments, the protein 17 
concentration in each well was determined using the Pierce BCA Protein Assay Kit 18 
(Thermo Scientific) after cell lysis in RIPA buffer (Sigma), and was used to calibrate 19 
the oxygen consumption data. 20 
ATP content measurements 21 
Intracellular ATP was measured in fibroblasts grown in DMEM-glucose culture 22 
medium using the ATP Bioluminescence Assay Kit HS II (Roche) according to 23 
manufacturer’s instructions. ATP concentration was calculated per 106 cells and 24 
expressed as percentage of control cells’ ATP concentration. 25 
Protein extraction for DIGE analysis 26 
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Whole protein extracts were prepared for each cell line. Samples were cleaned 1 
with the 2D Clean-up Kit (GE Healthcare) and stored overnight in acetone at -20 °C. 2 
Pellets were resuspended in 50 μl DIGE Buffer (10 mM Tris, 7 M urea, 2 M thiourea, 3 
2% CHAPS). Protein concentration was determined using the Bradford reagent 4 
(BioRad). 5 
DIGE Experimental Design and Protein Labeling 6 
The proteomics comparison between whole protein extracts from four controls 7 
(C) and four patient-derived (P) fibroblasts was performed across four DIGE gels using 8 
the same pooled sample internal standard (consisting on an equal mix of the eight 9 
samples in the experiment) to reduce inter gel variations. This allows the straight 10 
comparison of all samples regardless how the sample pairings were selected. Proteins in 11 
each sample were fluorescently tagged with a set of matched fluorescent dyes according 12 
to the manufacturer’s protocol for minimal labeling (GE Healthcare). To eliminate any 13 
dye-specific labeling artifacts, two samples of each group (C and P) were labeled with 14 
Cy3, and the other two were labeled with Cy5. The pooled sample internal standard was 15 
always Cy2-labeled. In every case, 400 pmol of dye was used for 50 µg of protein. 16 
Briefly, labeling was performed for 30 min on ice in darkness, and the reaction was 17 
quenched with 1 µl of 10 mM L-lysine for 10 min under the same conditions. 18 
2D Electrophoresis and Imaging of Cy-labeled Proteins 19 
The four pairs of Cy3- and Cy5-labeled samples (each containing 50 µg of 20 
protein) were combined and mixed with a 50 µg aliquot of the Cy2-labeled pooled 21 
standard. The mixtures containing 150 µg of protein were diluted 1:1 with rehydration 22 
buffer (7 M urea, 2 M thiourea, 4% CHAPS, 4% ampholytes (pH 3–11), and 200 mM 23 
DTT). The IPG strips (24 cm, nonlinear pH 3–11) were rehydrated overnight with 450 24 
µl of a rehydration buffer as above but with 2% ampholytes, 0.002% bromophenol blue, 25 
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and 97 mM DeStreak reagent instead of DTT. The labeled samples were then applied to 1 
the strips by cup loading on a manifold equipped IPGphor II IEF system (GE 2 
Healthcare). Isoelectric focusing was carried out for a total of 75 kVh using the 3 
following conditions: 1 h at 120 V, 2 h at 500 V, gradient from 500 V to 1000 V in 2 h, 4 
gradient from 1000 V to 5000 V in 6 h, and finally 10 h at 5000 V. Prior to the second 5 
dimension run, the strips were equilibrated first for 12 min in equilibration buffer (100 6 
mM Tris-HCl (pH 8.0), 6 M urea, 30% glycerol, 2% DTT and 2% SDS) and then for 7 
another 5 min in the same buffer supplemented with 2.5% iodoacetamide. The 8 
equilibrated strips were transferred onto 12% homogenous polyacrylamide gels (2.6% 9 
C) cast in low fluorescence glass plates using an Ettan-DALT six system (GE 10 
Healthcare). Electrophoresis was run at 1 W/gel for about 18 h at 20 °C.  11 
The differentially labeled co-resolved proteins within each gel were imaged at a 12 
resolution of 100 dots/inch using a Typhoon 9400 laser scanner (GE Healthcare). Cy2-, 13 
Cy3-, and Cy5-labeled images of each gel were acquired at excitation/emission values 14 
of 488/520, 523/580, and 633/670 nm, respectively. Gels were scanned directly between 15 
the glass plates, and the high resolution images (pixel size 100 μm) were exported for 16 
data analysis. After imaging for Cy dyes, the gels were removed from the plates and 17 
subjected to colloidal Coomassie staining. 18 
DIGE Data Analysis 19 
The DeCyder v6.5 software (GE Healthcare) was used for spot detection and 20 
determination of quantity, inter gel matching, and statistics. The differential in gel 21 
analysis (DIA) module was used for automatic spot detection and abundance 22 
measurements for each individual gel by comparing the normalized volume ratio of 23 
each spot from a Cy3- or Cy5-labeled sample to the corresponding Cy2 signal from the 24 
pooled sample internal standard. The DIA data sets from each individual gel were 25 
collectively analyzed using the biological variation analysis (BVA) module, which 26 
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allows inter gel matching and calculation of average abundance for each protein spot 1 
among the four gels of our study. Statistical significance was assessed for each change 2 
in abundance using Student’s t test and analysis of variance analyses. We considered 3 
statistical significance to be at the 95% confidence level (p<0.05) when standardized 4 
average spot volume ratios exceeded 1.2 in the four analyzed gels (i.e. 12 analyzed 5 
images). Calculation of experimental molecular weight and pI for each differential 6 
protein spot was carried out using the PDQuest 7.3.1 computer software (Biorad).  7 
Unsupervised principal component analysis (PCA), hierarchical clustering (HC), 8 
and k-means clustering analyses were performed using the DeCyder extended data 9 
analysis module on the group of spots identified as significantly changed. These 10 
multivariate analyses clustered the individual Cy3- and Cy5-labeled samples based on 11 
collective comparison of expression patterns from the set of proteins. The groups of 12 
protein expression characteristics are represented by each data point in the PCA plots 13 
and by each column in the HC expression matrixes.  14 
Mass Spectrometry Analysis 15 
The gel spots of interest were manually excised from the gels and transferred to 16 
microcentrifuge tubes. Samples selected for analysis were washed twice with water, 17 
shrunk with 100% ACN, and dried in a Savant SpeedVac. Then samples were reduced 18 
with DTT, alkylated with iodoacetamide, and subsequently digested with 12.5 ng/µl 19 
sequencing grade trypsin (Roche Applied Science) for at least 6 h at 37 °C. After 20 
digestion, the supernatant was collected, and 1 µl was spotted onto a MALDI target 21 
plate (384 spot Teflon®-coated plates) and allowed to air dry at room temperature. 22 
Subsequently, 0.5 µl of a 3 mg/ml solution of α-cyano-4-hydroxy-transcinnamic acid 23 
matrix in 0.1% TFA and 50% ACN was added to the dried peptide digest spots and 24 
again allowed to air dry. The samples were analyzed using the MALDI-TOF/TOF mass 25 
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spectrometer 4800 Proteomics Analyzer and 4000 Series ExplorerTM software 1 
(Applied Biosystems). MALDI-TOF spectra were acquired in reflector positive ion 2 
mode using 1000 laser shots per spectrum. Data Explorer version 4.2 (Applied 3 
Biosystems) was used for spectra analyses and generating peak picking lists. All mass 4 
spectra were internally calibrated using autoproteolytic trypsin fragments and externally 5 
calibrated using a standard peptide mixture (Sigma Aldrich). TOF/TOF fragmentation 6 
spectra were acquired by selecting the 10 most abundant ions of each MALDI-TOF 7 
peptide mass map (excluding trypsin autolytic peptides and other known background 8 
ions) and averaging 2000 laser shots per fragmentation spectrum. The parameters used 9 
to analyze the data were a signal to noise threshold of 20, a minimum area of 100, and a 10 
resolution higher than 10,000 with a mass accuracy of 20 ppm. 11 
Online Tools and Database Search 12 
The monoisotopic peptide mass fingerprinting data obtained from MS and the 13 
amino acid sequence tag obtained from each peptide fragmentation in MS/MS analyses 14 
were used to search for protein candidates using Mascot version 1.9 (Matrix Science). 15 
Peak intensity was used to select up to 50 peaks per spot for peptide mass fingerprinting 16 
and 50 peaks per precursor for MS/MS identification. Tryptic autolytic fragment-, 17 
keratin-, and matrix-derived peaks were removed from the data set used for the database 18 
search. The searches for peptide mass fingerprints and tandem MS spectra were 19 
performed in the Swiss-Prot release 53.0 and TrEMBL release 37.0 databases without 20 
taxonomy restriction, containing 269,293 and 4,672,908 sequence entries, respectively, 21 
for each software version and database release. Fixed and variable modifications were 22 
considered (Cys as S-carbamidomethyl derivate and Met as oxidized methionine, 23 
respectively), allowing one trypsin missed cleavage site and a mass tolerance of 50 24 
ppm. For MS/MS identifications, a precursor tolerance of 50 ppm and MS/MS fragment 25 
tolerance of 0.3 Da were used. Identifications were accepted as positive when at least 26 
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five matching peptides and at least 20% of the peptide coverage of the theoretical 1 
sequences matched within a mass accuracy of 50 or 25 ppm with internal calibration. In 2 
every case probability scores were significant at p < 0.01.  3 
Intracellular localization of the identified proteins was predicted from the amino 4 
acid sequence using the PSORT II software (http://psort.hgc.jp/form2.html). Mapping 5 
of proteins identified by mass spectrometry, and database search onto existing pathways 6 
and cellular networks was carried out using the KEGG Pathway 7 
(http://www.genome.jp/kegg/pathway.html) and STRING 9.1 (http://string-db.org/) 8 
Databases [26, 27]. 9 
Western-blot analysis 10 
The supernatants (corresponding to 10 µg of whole cell extracts) were mixed 11 
with an equal volume of tricine sample buffer (Biorad) containing 2% (v/v) 2-12 
mercaptoethanol. The mixtures were boiled for 5 min and proteins were separated on 13 
standard 10% SDS-PAGE gels and transferred onto PROTRANTM nitrocellulose 14 
membranes (Whatman®). Membranes were blocked in phosphate-buffered saline (pH 15 
7.4) containing 0.1% Tween-20 and 5% non-fat dried milk for at least 2 hours at room 16 
temperature. The blots were then hybridized with antibodies raised against the 17 
following proteins: lamin-A/C (Santa Cruz), gelsolin (Abcam), glyceraldehyde 3 18 
phosphate dehydrogenase (Mitosciences), DJ-1 (Abcam) and β-actin (Sigma). 19 
Peroxidase-conjugated anti-mouse or anti-rabbit IgGs (Molecular Probes) were used as 20 
secondary antibodies. Immunoreactive bands were detected by chemiluminescence with 21 
ECL® prime reagents (Amersham Biosciences) in a G:Box Chemi IR6 Image Analyzer 22 
(Syngene). Quantitative changes in band intensities were evaluated by densitometric 23 
scanning with the Image J software and the densitometric values were normalized to 24 
those of the loading controls. 25 
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Indirect Immunofluorescence 1 
Cells were fixed with 4% paraformaldehyde for 15 min and permeabilized for 15 2 
min with 0.1% Triton X-100. Cells were incubated in blocking buffer containing 10% 3 
goat serum for 1h at room temperature. Immunodetection was performed with the 4 
previously mentioned primary antibodies, and FITC (MitoSciences) and Alexa 488 5 
(Invitrogen) were used as secondary antibodies. After appropriate rinsing, cover slips 6 
were mounted in ProLong Gold antifade reagent (Molecular Probes) on glass slides, and 7 
cells were viewed with a Zeiss LSM 510 Meta confocal microscope and a 63x 8 
planapochromat objective.  9 
Amino acids concentrations of cell culture media 10 
Approximately 1.5x106 fibroblasts were plated and cultured for 48 hours in 11 
serum-free DMEM supplemented with 100 IU/ml penicillin/streptomycin at 37ºC and 12 
5% CO2. Cell culture media were collected and the samples (200 µL) were 13 
deproteinized for 20 minutes with 20 µL of 50% sulfosalicylic acid, centrifuged, and the 14 
protein-free supernatant was mixed with a lithium citrate buffer (1:1). Cationic 15 
exchange chromatography was performed with a stepwise elution of free amino acids 16 
with citrate buffers and detection with ninhydrin, using a Biochom 30 amino acid 17 
analyzer (Biochrom Ltd.) according to the manufacturer´s specifications. The amino 18 
acids concentrations were expressed in µmol/L. The protein concentration on each 19 
sample was determined with the Pierce BCA Protein Assay Kit (Thermo Scientific) and 20 
used to normalize the amino acid concentration data.  21 
GAPDH and PDH enzyme activities 22 
 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity was measured 23 
using a colorimetric GAPDH Assay Kit (ScienCell™) and pyruvate dehydrogenase 24 
(PDH) activity was determined using the PDH Enzyme Activity Dipstick Assay Kit 25 
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(Mitosciences), according to the manufacturers’ protocols. Enzyme activities were 1 
normalized by the protein concentration on each sample. 2 
Data Analysis 3 
 Unless indicated, all experiments were performed at least in triplicate and results 4 
were presented as mean ± standard deviation (SD) values. Statistical p values were 5 
obtained by application of either Student’s t test or Mann-Whitney U test using the 6 
SPSS v15.0 program. 7 
8 
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RESULTS 1 
Decreased oxygen consumption and ATP levels in fibroblasts with mutations in 2 
BCS1L 3 
To shed light on the metabolic alterations and signaling pathways affected by 4 
mitochondrial respiratory chain complex III enzyme deficiency, we first measured 5 
oxygen consumption rates (OCR), intracellular ATP levels and extracellular 6 
acidification rates (ECAR) in genetically and biochemically characterized primary skin 7 
fibroblasts from four healthy donors (C) and four complex III-deficient patients (P) 8 
harboring mutations in the BCS1L gene [15, 16, 18, 22]. Measurements showed a 9 
significant reduction of  ̴30% in the oxygen consumption rates (Figure 1A) and a 10 
decrease of  ̴70% in the intracellular ATP concentration (Figure 1B) of BCS1L mutant 11 
fibroblasts compared with the controls. No significant differences were observed in the 12 
extracellular acidification rates between these two sample groups (Figure 1C). The 13 
individual values obtained for each patient´s cell line are shown in Supplemental Figure 14 
1. 15 
2D-DIGE analysis of fibroblasts with mutations in BCS1L 16 
We next performed a 2D-DIGE proteomics analysis in whole cell extracts from 17 
eight samples corresponding to four controls and four fibroblasts with mutations in 18 
BCS1L (Figure 2). After four-plex 2D-DIGE, three individual images were obtained 19 
from each gel, corresponding to Cy2-, Cy3-, and Cy5-labeled samples. The 12 gel 20 
images were analyzed using the DeCyder software. DIA allowed the detection of an 21 
average of 1817 protein spots on each image with a 2.73 % coefficient of variation 22 
between them. Then inter image spot matching was carried out by BVA. In this step, an 23 
average of 1456 spots was matched on the gels (2.71 % coefficient of variation), and 24 
their average abundances among the 12 images of our study were calculated. We 25 
considered changes within a 95% confidence interval (p <0.05) and standardized 26 
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average spot volume ratios exceeding 1.2 in the four analyzed gels. This analysis 1 
yielded a total of 52 protein species common to the 12 gel images that were 2 
unambiguously identified as significantly altered in complex III deficiency: 34 spots 3 
were significantly and reproducibly increased in all four patients´ fibroblasts relative to 4 
the four controls, and 18 spots were decreased. These 52 spots are depicted on a 5 
representative DIGE gel image shown in Figure 3. 6 
Identification of differentially expressed proteins in complex III-deficient 7 
fibroblasts 8 
For the identification of proteins, spots were selected, digested in gel, and 9 
analyzed by MALDI-PMF-MS. A Mascot database search using the PMF spectra 10 
allowed the identification of the proteins present in 39 out of the 52 spots obtained from 11 
duplicate gels (spots 7, 12, 29, 33, 35, 38, 40, 46, 47, 48, 49, 50 and 51 failed to be 12 
identified). In nine cases (spots 2, 9, 15, 21, 23, 24, 32, 39 and 52), two different 13 
proteins were identified on the same spot, and we also detected 16 redundancies because 14 
of posttranslational modifications or proteolysis. The last 7 proteins from the group of 15 
52 were identified by tandem MS. Altogether 39 different proteins were identified as 16 
altered in BCS1L-associated complex III deficiency, as listed in Table 1 and 17 
Supplemental Table 1 with detailed information comprising experimental and 18 
theoretical molecular weight and pI values, accession number, and identification 19 
parameters.  20 
Multivariate Statistical Analysis 21 
We sought to establish biological significance of the protein changes by 22 
performing multivariate statistical tests on the proteins identified by DIGE-MS. As 23 
shown in Figure 4A, principal component analysis displayed a good separation of the 24 
control and patients´ sample groups. For the 52 protein spots altered in the DIGE 25 
analysis, the first principal component (PC1) distinguished 73.9% of the variance, and 26 
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an additional 10.6% variation was distinguished by the second principal component 1 
(PC2). A second type of pattern analysis, the k-means algorithm, was carried out on 2 
these 52 protein forms. This analysis clustered them into four groups displaying similar 3 
patterns (Figure 4B). The proteins in each k-means cluster are listed in Supplemental 4 
Table S2. Finally, hierarchical clustering analysis (Figure 4C) established two different 5 
patterns in this group of proteins and clearly differentiated these two diverse profiles, 6 
clustering patients-derived (marked within a green square in Figure 4C) and control 7 
fibroblasts (orange square). Protein spot numbering indicated in the heat map correlates 8 
with the information shown in Table 1.  9 
The variations in the expression levels of some of the proteins altered in the 10 
complex III deficient-fibroblasts were validated using Western-blot and 11 
immunofluorescence analyses (Figure 5). These analyses confirmed decreased levels of 12 
nuclear lamin-A/C, and increased levels of cytoplasmic gelsolin, glyceraldehyde 3 13 
phosphate dehydrogenase (GAPDH), and the endoplasmic reticulum DJ-1 protein in the 14 
BCS1L mutant fibroblasts compared with the controls.  15 
Cellular pathways altered in complex III-deficient fibroblasts 16 
A database search was carried out to analyze the predicted subcellular 17 
localization of these proteins and to assign them into different functional groups. Most 18 
of the identified proteins were predicted as mainly cytosolic (69%), with an additional 19 
15% being predicted as nuclear, 8% associated with other membrane structures or 20 
located in other subcellular organelles, such as the endoplasmic reticulum, vacuoles, or 21 
peroxisomes, and only 8% being predicted as purely mitochondrial.  22 
Bioinformatics analysis using the KEGG Pathway and STRING 9.05 Databases 23 
[26, 27] enabled the characterization of biological association networks related to these 24 
differentially expressed proteins that allowed us to identify the biochemical pathways 25 
that could be altered in complex III deficiency. According to their specific cellular roles, 26 
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the 39 proteins whose expression was altered in the BCS1L mutant fibroblasts were 1 
divided into five different functional categories. The main protein group (31%) is 2 
involved in metabolic pathways that primarily regulate energy metabolism (specifically 3 
affecting glycolysis, the TCA cycle and the pentose phosphate and hexosamine 4 
pathways) and iron homeostasis. The remainder proteins are involved either in the 5 
regulation of gene expression at the levels of transcription, DNA replication or protein 6 
synthesis (23%), are structural or cytoskeleton- related (23%), take part in intracellular 7 
transport events and cell signaling (13%), or are either chaperones or regulatory proteins 8 
involved in cellular responses to metabolic and oxidative stress (10%). 9 
We next aimed to physiologically validate some of the predicted functional 10 
adaptations of human cultured fibroblasts to mitochondrial complex III deficiency. Our 11 
DIGE analysis showed increased levels of two enzymes involved in the glycolytic 12 
pathway, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and α-enolase, 13 
suggesting the up-regulation of glycolysis as a way to produce ATP when the 14 
respiratory chain is malfunctioning. Triplicate spectrophotometric measurements 15 
revealed an increase of  ̴52% in the mean GAPDH enzyme activity of fibroblasts with 16 
mutations in BCS1L compared with that of the controls, suggestive of an up-regulation 17 
of the glycolytic flux (Figure 6A). Proteomics also revealed decreased levels of 18 
dihydrolipoyl dehydrogenase (DLD) in the BCS1L mutant fibroblasts. DLD is an 19 
enzyme involved in the mitochondrial glycine cleavage system, which is also a key 20 
component of the pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and 21 
branched-chain alpha-ketoacid dehydrogenase complexes, therefore playing crucial 22 
roles in key steps of the intermediary metabolism. Defects in DLD are involved in the 23 
development of maple syrup urine disease (MSUD) [OMIM: 248600], a metabolic 24 
disorder caused by an enzyme defect in the catabolic pathway of the branched-chain 25 
amino acids, which accumulate together with their corresponding keto acids, leading to 26 
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encephalopathy and progressive neurodegeneration [28]. As expected, the decreased 1 
DLD protein levels provoked a decrease of ̴43% in the mean PDH enzyme activity of 2 
patients´ fibroblasts compared with the controls (Figure 6B). We next analyzed whether 3 
the reduced DLD levels in BCS1L mutant fibroblasts also led to the accumulation of its 4 
reaction precursors, such as glycine or branched-chain amino acids. Cells were grown 5 
for 48 hours in serum-free medium, and the amino acids concentrations from cell 6 
culture media were measured in triplicate (Figure 6C). A prominent increase in the 7 
concentration of the branched-chain amino acids leucine, isoleucine, and valine was 8 
observed in patients´ fibroblasts compared with the controls, together with raised levels 9 
of other amino acids, such as glutamine, threonine, glycine, serine, cysteine, 10 
methionine, tyrosine, phenylalanine, lysine, histidine, tryptophan and arginine. These 11 
data support the alteration of branched-chain amino acids catabolism probably as a 12 
consequence of the DLD defect, although the increased levels of most amino acids 13 
could be indicative of a general activation of protein catabolism in complex III-deficient 14 
fibroblasts. Based in the results obtained from the DIGE and validation analyses, a 15 
hypothetical model of the physiological adaptations that take place in fibroblasts with 16 
mutations in BCS1L is proposed in Figure 7. 17 
 18 
19 
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DISCUSSION 1 
In this work we have analyzed the cellular and metabolic adaptations that take 2 
place in primary skin fibroblasts from patients with mitochondrial complex III 3 
deficiency. To identify these mechanisms, we undertook a high-resolution differential 4 
proteomic analysis of cultured skin fibroblasts from four complex III-deficient patients 5 
harboring diverse mutations in the BCS1L gene and four healthy controls. This 6 
experimental strategy yielded a total of 39 proteins successfully identified by mass 7 
spectrometry that were differentially expressed between control and patients´ samples. 8 
The protein profile characteristic for BCS1L-associated complex III deficiency 9 
suggested alterations in pathways controlling energy metabolism and cellular 10 
homeostasis, cytoskeleton formation and maintenance, gene expression and protein 11 
synthesis, intracellular transport and signal transduction, and cell stress responses.  12 
Metabolic alterations 13 
The main proteins group whose expression was altered in the BCS1L mutant 14 
fibroblasts was involved in energy metabolism. In complex III-deficient fibroblasts the 15 
main altered molecular event is probably a limited respiration-coupled ATP production 16 
through the OXPHOS system, which would force a metabolic switch that would enable 17 
to obtain energy primarily from glycolysis and alternative catabolic processes, with a 18 
parallel reduction or blockage of alternative glucose- and ATP-consuming pathways, 19 
such as the phosphate pentose and hexosamine pathways, and a decreased TCA cycle.  20 
During glycolysis, glucose is converted into pyruvate and the free energy released 21 
is used to form the energy-rich molecules ATP and NADH. In fibroblasts with BCS1L 22 
mutations this pathway is affected at the levels of three enzymes, presenting reduced 23 
levels of fructose-bisphosphate aldolase A (ALDOA), and increased levels of 24 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and α-enolase. ALDOA 25 
catalyses the reversible conversion of fructose 1,6-bisphosphate into glyceraldehyde 3- 26 
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phosphate (G3P) and dihydroxyacetone phosphate (DHAP). Since ATP is required for 1 
the synthesis of fructose 1,6-bisphosphate in the first steps of glycolysis, it is possible 2 
that the reduced ALDOA levels are a consequence of the limited availability of its 3 
substrate. This would imply reduced levels of G3P and DHAP, which are necessary 4 
substrates for the glycolytic energy generation phase in which ATP and NADH are 5 
produced. The first step of this second phase of glycolysis is catalyzed by GAPDH, 6 
which converts G3P into D-glycerate 1,3-bisphosphate. α-enolase is responsible for the 7 
penultimate step of glycolysis in which the catalysis of 2-phosphoglycerate to 8 
phosphoenol pyruvate takes place. Therefore, the increased levels of GAPDH and α-9 
enolase could take place as compensatory responses to increase the glycolytic flux 10 
efficiency and pyruvate biosynthesis, which in aerobic conditions is transformed 11 
through the pyruvate dehydrogenase complex into acetyl-CoA, usable in the 12 
mitochondrial TCA cycle to carry out cellular respiration and ATP production. 13 
However, in fibroblasts with mutations in BCS1L anaerobic glycolysis would not 14 
increase enough to compensate for a deficient oxidative phosphorylation, since ATP 15 
levels remained significantly lower in the patients´ fibroblasts compared with controls.  16 
Our proteomic analysis suggested alterations in both pyruvate conversion and the 17 
TCA cycle activities due to reduced levels of two key mitochondrial enzymes: 18 
dihydrolipoyl dehydrogenase (DLD) and dihydrolipoyl lysine-residue 19 
succinyltransferase (DLST). DLD is a multifunctional enzyme that catalyzes NADH 20 
oxidation and plays an important role in redox metabolism [29, 30]. DLD is a functional 21 
component of the pyruvate dehydrogenase complex, thus decreasing its levels could 22 
compromise the conversion of pyruvate into acetyl-CoA and lead to the accumulation of 23 
cytosolic pyruvate, which is probably transformed by the enzyme lactate dehydrogenase 24 
into lactate and NAD+ to keep glycolysis active. The fact that BCS1L mutant fibroblasts 25 
did not generally present increased acidification of cell culture media suggests that, 26 
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despite glycolysis up-regulation, the accumulating pyruvate could undergo a rapid 1 
transamination to alanine in order to avoid environmental acidification. Besides, DLD is 2 
a component of the branched-chain α-ketoacid dehydrogenase complex (BCKDC), 3 
involved in the catabolism of branched-chain amino acids and their derivatives. 4 
Reduced DLD levels could therefore explain the accumulation of branched-chain amino 5 
acids observed in fibroblasts with mutations in BCS1L, although the general increase in 6 
amino acids levels might be indicative of a broader activation of protein catabolism. 7 
Both DLD and DLST are also components of the oxoglutarate dehydrogenase complex, 8 
which catalyzes the conversion of α-ketoglutarate to succinyl-CoA in the TCA cycle. 9 
Therefore, the decreased DLD and DLST levels could presumably compromise the 10 
normal flux and favor the accumulation of intermediate metabolites of the TCA cycle. 11 
In agreement with our results, the liver metabolomic profile of late disease stages of 12 
GRACILE Syndrome in transgenic mice showed decreased levels of G3P and DHAP, 13 
decreased activities and accumulation of intermediate metabolites of the TCA cycle, and 14 
increased levels of amino acids and long-chain acylcarnitines [31]. 15 
According to our data, the phosphate pentose (PP) pathway would also be down-16 
regulated in favor of glycolysis, since both routes require glucose oxidation in their 17 
initial steps. There are two distinct phases in the PP pathway, the oxidative phase, in 18 
which most of the cellular reducing energy in form of NADPH is generated, and the 19 
non-oxidative phase, in which 5-carbon sugars are synthesized for nucleotide and 20 
nucleic acids biogenesis. The BCS1L mutant fibroblasts showed decreased levels of two 21 
initial PP pathway rate-limiting enzymes: glucose-6-phosphate dehydrogenase 22 
(G6PDH) and hexose-6-phosphate dehydrogenase (H6PD). G6PDH converts glucose-6-23 
phosphate into 6-phosphoglucono-δ-lactone whilst reducing NADP+ to NADPH. 24 
NADPH is necessary for lipid and nucleic acids biosynthesis, and it is used by the 25 
glutathione reductase enzyme to reduce glutathione, which is in turn oxidized by 26 
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glutathione peroxidase to convert reactive hydrogen peroxide (H2O2) into H2O. 1 
Therefore, NADPH re-oxidation constitutes an essential step to prevent the 2 
accumulation of hydroxyl free radicals and to ensure protection against oxidative 3 
damage. It is reasonable to expect that decreased G6PDH levels may hinder H2O2 4 
detoxification by cutting the NADPH supply, which would explain the high H2O2 levels 5 
and the alterations in the cellular antioxidant defenses previously observed in fibroblasts 6 
with mutations in BCS1L [22]. H6PD is the initial component of the PP pathway inside 7 
the endoplasmic reticulum (ER) that generates NADPH for ER enzymes, and its 8 
blockage may activate the cellular stress response known as unfolded protein response 9 
(UPR) [32], in agreement with the up regulation of the UPR proteins GRP78, ERP29 10 
and ERP70 observed in the mutant fibroblasts (see ahead). The presumed reduction in 11 
the levels of the G6PDH and H6PD reaction products could potentially provoke a 12 
compensatory raise in the levels of the second enzyme of the PP pathway, 6-13 
phosphogluconolactonase (PGLS), as revealed by our DIGE analysis. 14 
As a consequence to the partial blockage of the PP pathway, lipids as well as 15 
nucleic acids biosynthesis would be hampered. Accordingly, reduced levels of C-1-16 
tetrahydrofolate synthase were detected. This enzyme participates in the synthesis of 17 
tetrahydrofolate derivatives, essential cofactors used in amino acids metabolism and for 18 
the synthesis of purines and pyrimidines. The BCS1L mutant fibroblasts also showed 19 
increased levels of adenine phosphoribosyltransferase (APRT) and glucosamine-6-20 
phosphate isomerase 1 (GNPDA1). APRT catalyzes the formation of AMP from the 21 
adenine rescued from DNA and RNA degradation in the purine nucleotide 22 
salvage pathway, an essential route in cells unable to perform de novo synthesis of 23 
nucleic and ribonucleic acids. These increased APRT levels agree with the AMP 24 
accumulation detected in late disease stages of GRACILE Syndrome in transgenic mice 25 
[31]. GNPDA1 participates in the hexosamine biosynthetic pathway, whose end-26 
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products will be used for making glycosaminoglycans, proteoglycans, and glycolipids 1 
that are key structural components of cell membranes, extracellular matrix and 2 
connecting tissues. GNPDA1 catabolyzes the reversible conversion of D-glucosamine-3 
6-phosphate into D-fructose-6-phosphate, which could be used as a direct substrate in 4 
the glycolitic pathway possibly at the expense of cellular structural components. 5 
Noteworthy, the ferritin light chain (FTL) levels were increased in the BCS1L 6 
mutant fibroblasts. Ferritin is the primary intracellular iron-storage protein complex and 7 
keeps iron in a soluble and nontoxic state. It is composed of heavy and light ferritin 8 
chains, and variations in its subunits composition may affect the rates of iron uptake and 9 
release in human cells. Many patients harboring mutations in the BCS1L gene present 10 
with iron overload, increased ferritin levels and low iron binding capacities, and based 11 
on these clinical evidences, a role for BCS1L in iron homeostasis was proposed [14]. 12 
Since ferritin is up-regulated in response to different types of cellular stress [33], it is 13 
plausible to speculate that the increased FTL levels could constitute a secondary 14 
response to the metabolic and oxidative stresses generated by the BCS1L mutations. 15 
Alterations in the regulation of gene and protein expression 16 
The second proteins group involved those participating in the regulation of gene 17 
and protein expression, in agreement with the observed alterations in nucleic and amino 18 
acids metabolisms via blockage of the TCA cycle and the PP pathway. The BCS1L 19 
mutant cells showed reduced levels of the SND1, Lamin-A/C, XRCC6 and DDX1 20 
proteins. SND1 is a component of the RNA-induced silencing complex (RISC) that 21 
plays a dual role in the regulation of transcription and pre-mRNA splicing [34]. Lamin-22 
A/C is a constituent of the nuclear lamina, a protein matrix involved in nuclear 23 
stability, chromatin structure and gene expression that regulates cell cycle and apoptosis 24 
[35]. XRCC6 is a subunit of the ATP-dependent DNA helicase 2, which is required for 25 
the non-homologous end joining (NHEJ) pathway of DNA repair [36]. Alterations in 26 
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this pathway may cause genomic instability and cell cycle arrest and it is associated 1 
with several human genetic syndromes [37]. The ATP-dependent RNA helicase DDX1 2 
belongs to the DEAD box protein family, implicated in a number of cellular processes 3 
that involve the modification of RNA secondary structures. This protein plays an RNA 4 
clearance role at DNA double-strand break sites, thereby facilitating the template-5 
guided repair of transcriptionally active regions of the genome [38]. The BCS1L mutant 6 
fibroblasts also exhibited mildly decreased levels of the eukaryotic translation initiation 7 
factor EIF3H. These cells possibly compensate for those alterations by up-regulating 8 
other gene expression regulatory proteins, such as cytoplasmic asparagine-tRNA ligase 9 
(NARS), the abhydrolase domain-containing protein 14B (ABDH14B), or the 10 
heterogeneous nuclear ribonucleoprotein Q (hnRNP Q). NARS contributes to the initial 11 
steps of protein biosynthesis by activating and transferring asparagine to specific tRNA 12 
molecules. ABDH14B is an unknown function enzyme that could be involved in 13 
activating nuclear transcription [39]. HNRPQ is an mRNA-binding protein implicated 14 
in translation regulation through miRNA-mediated repression of specific mRNAs [40], 15 
as well as in cellular stress responses by regulating p53 translation efficiency and 16 
thereby, cell cycle and apoptosis progression [41]. In oxidative stress conditions p53 is 17 
imported into mitochondria, where it interacts with the mitochondrial DNA (mtDNA) 18 
single-stranded binding protein (mtSSB) to promote mtDNA repair [42]. In agreement, 19 
the levels of the mtSSB protein, involved in mtDNA replication [43], were also raised. 20 
Since increased mitochondrial proliferation is commonly associated with respiratory 21 
chain defects, the mtSSB protein up-regulation would enable a dual oxidative stress-22 
induced response, allowing for the protection of mtDNA against oxidative damage 23 
lesions in parallel with enhancing mitochondrial biogenesis to compensate for the 24 
dysfunctional respiratory chain. These putative alterations in the regulation of gene and 25 
protein expression are suggestive of cell survival adaptations that could ultimately affect 26 
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cell division and apoptosis. In this regard, the BCS1L mutant fibroblasts exhibited slow 1 
growth rates in glucose media and apoptotic cell death [22]. 2 
Alterations in cytoskeleton formation and maintenance 3 
In eukaryotic cells, the cytoskeleton is composed of actin filaments, intermediate 4 
filaments and microtubules that play important roles in the organization and distribution 5 
of the internal cellular structures, in the intracellular transport of organelles and 6 
secretory vesicles, and in cellular division. The BCS1L mutant fibroblasts showed 7 
putative alterations in cytoskeleton formation through the reduced levels of a number of 8 
structural constituents, such as vinculin, moesin, or the WDR1 protein, which may 9 
function either as cross-linkers between plasma membranes and actin-10 
based cytoskeletons or are involved in the assembly/disassembly of actin filaments, or 11 
such as vimentin, an intermediate filament scaffolding protein that plays a role in 12 
anchoring the organelles position in the cytosol, or alpha-tubulin, a major structural 13 
component of the microtubules. Cytoskeleton disorganization could thus take place as a 14 
consequence of the decreased levels of its key structural components, which could be 15 
potentially compensated by the up-regulation of regulatory proteins involved in the 16 
organization and assembly of these structures. Such could be the case for the Rho 17 
GTPase activating protein p50rhoGAP (or CDC42GAP), involved in actin cytoskeleton 18 
remodeling through the activation of signal transduction pathways from plasma-19 
membrane receptors [44]; the dihydropyrimidinase-related protein CRMP-2, that 20 
regulates actin cytoskeleton organization and microtubules assembly [45]; septin-11, a 21 
cytoskeletal GTPase that associates with cellular membranes, actin filaments and 22 
microtubules, thus playing a role in cytoskeleton reorganization and cellular architecture 23 
maintenance [46]; or gelsolin, a calcium-dependent actin-binding protein that regulates 24 
actin filaments assembly and disassembly [47]. Since mitochondria are well known to 25 
bind and move along microtubules and actin filaments, a hypothetical destructuration of 26 
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the cytoskeleton could explain the predominantly fragmented phenotype of the 1 
mitochondrial network in BCS1L mutant fibroblasts, in the absence of significant 2 
alterations in proteins involved in the mitochondrial fusion and fission processes [22]. 3 
Of note, cytoskeleton constituents may act as powerful regulatory checkpoints 4 
that directly impact mitochondrial metabolism. For instance, dimeric tubulin physically 5 
interacts with VDAC, a component of the major ion channel of the mitochondrial outer 6 
membrane, to regulate respiration and energy metabolism [48]. Most glycolytic 7 
enzymes have been shown to bind to microtubules, and their enzyme activities depend 8 
on the bound-unbound state [49]. By this type of control, cytoskeleton components 9 
could selectively adapt metabolic fluxes between mitochondria and the cytosol to 10 
alterations in metabolic conditions, and provide a functional link between mitochondrial 11 
metabolism, the internal cellular organization and cell cycle. 12 
Alterations in intracellular trafficking and signal transduction 13 
Complex III-deficient fibroblasts exhibited increased levels of proteins involved 14 
in cell signaling processes that couple gene expression to intracellular trafficking, such 15 
as the phosphatidylethanolamine-binding protein PEPBP1/RKIP, annexin 2, annexin 4 16 
and sorting nexin 6 (SNX6). RKIP is a master modulator of the MAP kinases, NF-κB 17 
and G-protein-mediated signaling pathways to control cellular growth, motility, 18 
apoptosis and genomic integrity [50]. Annexins are cytosolic proteins that bind 19 
negatively charged phospholipids present in the membrane walls in a Ca2+-dependent 20 
manner [51]. Annexin 2 (ANXA2) is a multifunctional protein that binds PIP2 21 
(phosphatidylinositol-4,5-bisphosphate) to facilitate actin assembly in the vicinity of the 22 
cell membrane [52], regulates post-transcriptional gene expression [53], and the 23 
biogenesis of multivesicular transport intermediates destined for late endosomes in the 24 
degradation pathway that leads to lysosomes [54]. Annexin A4 (ANXA4) is involved in 25 
the regulation of endo- and exocytosis, in ion-transport regulation and in the Ca2+-26 
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dependent modulation of the NF-κB signaling pathway [55]. SNX6 is a component of 1 
the retromer complex that mediates the retrograde trafficking of membrane proteins 2 
from endosomes to the trans-Golgi network (TGN), essential for the retrieval of 3 
membrane receptors [56]. This protein links the retromer to the microtubule motor 4 
complex that allows the long-range movement of endosomes from the cell periphery to 5 
the TGN [57]. Recent proteomic analyses identified SNX6 as an autophagosome 6 
component, suggesting a role for the retromer complex in mTOR-dependent autophagy 7 
[58]. Decreased levels of the COPII vesicle coat SEC24D protein were detected in the 8 
BCS1L mutant fibroblasts. The COPII vesicle coat promotes the anterograde transport 9 
of newly synthesized membrane proteins from the endoplasmic reticulum (ER) to the 10 
TGN, where SEC24 protein isoforms (A, B, C and D) mediate the selective export of 11 
ER transmembrane proteins by involving lipid rafts as early sorting platforms [59].  12 
These observations suggest a general up-regulation of the sorting machineries of 13 
transmembrane proteins to endosomes and lysosomes, probably as a way to retrieve 14 
important molecules for re-use in detriment of de novo protein synthesis, more energy 15 
consuming, or alternatively to get rid of dysfunctional organelles or molecules that 16 
might otherwise accumulate as a consequence of permanent oxidative damage. In 17 
agreement, our group has recently demonstrated that BCS1L mutant fibroblasts show 18 
increased bulk autophagy and an accumulation of vesicles, autophagic vacuoles and 19 
lysosomes as a result of a partial blockage of the autophagic flux [60]. This could be a 20 
consequence of the predicted cytoskeleton destructuration, since endosomal protein 21 
sorting requires localized polymerization of actin filaments and microtubules [57, 61].  22 
Alterations in cellular stress responses 23 
Metabolic and oxidative stress could elicit the activation of cellular stress 24 
responses in the BCS1L mutant fibroblasts, as evidenced by the raised levels of ER 25 
chaperones that take part in the Unfolded Protein Response (UPR), such as GRP78, 26 
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ERP29 and ERP70. This mechanism is activated in response to the accumulation of 1 
unfolded or misfolded proteins to restore the normal cellular functions by halting 2 
protein translation and activating signaling pathways that increase the expression of 3 
molecular chaperones that target oxidized proteins for proteasomal degradation [62]. 4 
Prolonged failure to adapt to ER stress will result in the UPR aiming towards apoptosis, 5 
which could explain the increased cell death observed in BCS1L mutant fibroblasts [22].  6 
PARK7/DJ-1 protein levels were also increased in the mutant cells. DJ-1 plays an 7 
important protective role against oxidative stress and cell death. Under normal 8 
conditions, DJ-1 is predominantly located in the cytoplasm and, in response to oxidative 9 
stress, it translocates to the mitochondrion and subsequently to the nucleus, where it acts 10 
as a redox sensitive chaperone. Within mitochondria, it seems to cooperate with the 11 
PINK1/parkin machinery to regulate the correct function and morphology of the 12 
mitochondrial network and for the autophagy of dysfunctional mitochondria [63, 64]. 13 
Possibly, the metabolic and oxidative stress observed in the BCS1L mutant fibroblasts 14 
might induce the expression of proteins with protective roles against ROS and cell death 15 
induction. These expression variations probably imply further alterations in gene 16 
expression to promote cellular adaptations to metabolic and oxidative damage. 17 
CONCLUSIONS 18 
The DIGE technology has allowed us to obtain a protein profile characteristic for 19 
fibroblasts with mutations in BCS1L. Current evidence suggests a general defect in 20 
energy metabolism and a shift towards anaerobic glycolysis and catabolic processes as 21 
alternative ways to obtain ATP, and a whole cellular genetic and metabolic 22 
reprogramming to adapt cell survival to mitochondrial dysfunction-elicited oxidative 23 
stress. Gaining deeper insight into these functional adaptations will pave the way 24 
towards biomarkers detection and future therapeutic strategies for complex III 25 
deficiency.26 
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FIGURE LEGENDS 1 
Figure 1. Oxygen consumption, ATP levels and glycolytic flux in complex III-2 
deficient fibroblasts. (A) Real-time analysis of oxygen consumption rates (OCR) in 3 
control (n=4) and patients' fibroblasts (n=3) respiring in 1 g/l glucose-containing 4 
medium. Student’s t test: ***(p<0.001). (B) Intracellular ATP content in control (n=4) 5 
and patient's fibroblasts (n=4) grown in 1 g/l glucose-containing medium. Mann-6 
Whitney U test: **(p<0.01) (C) Extracellular acidification rates (ECAR) as an indicator 7 
of lactate release to the extracellular medium in control (n=4) and patient's fibroblasts 8 
(n=3). All measurements were performed at least six times per sample. Data are 9 
expressed as percentages of the mean values obtained in controls ± standard deviation. 10 
Figure 2. DIGE experimental design. Fibroblasts were obtained from age and sex-11 
matched control individuals (C1-C4) and complex III-deficient patients (P1-P4). Cells 12 
were balanced for passage number and homogenized prior to protein extraction. Whole 13 
cell extracts were purified and labeled with the corresponding Cy dyes. Samples were 14 
then mixed and resolved on four independent DIGE gels. Three fluorescence images 15 
were obtained from each gel and subjected to image analysis using DeCyder software. 16 
After biological variation analysis, spots that exhibited significant quantity 17 
modifications in patients´ fibroblasts were identified by MALDI-TOF/ TOF mass 18 
spectrometry. Finally, extended data analysis (EDA) and KEGG and STRING database 19 
searches were carried out to gain further information about protein alterations that are 20 
inherent to complex III deficiency. 21 
Figure 3. Representative Cy2-labeled internal standard proteome map indicating 22 
the proteins altered in complex III-deficient fibroblasts. Proteins were resolved in a 23 
3–11 (nonlinear) pH range on the first dimension and on 12% acrylamide gels on the 24 
second dimension. Proteins that exhibited significant expression alterations in patients´ 25 
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samples were identified by MALDI-TOF or MALDI-TOF/TOF mass spectrometry. 1 
These proteins are listed in Table 1 by the same number as that in the figure. 2 
Figure 4. Unsupervised multivariate analysis of the DIGE assay. (A) Principal 3 
component analysis clustered the 8 individual Cy3- and Cy5-labeled expression maps 4 
into control (orange) or patients´ (green) groups differentiated by two principal 5 
components that distinguish the variance. (B) k-means cluster analysis showing the four 6 
different clusters that group the identified proteins. q, cluster quality; no, number of 7 
proteins belonging to each cluster. The set of proteins corresponding to each cluster is 8 
listed in Supplemental Table S2. (C) Unsupervised hierarchical clustering of the 8 9 
independent images based on the global expression patterns of the 52 protein spots that 10 
were altered in complex III-deficient fibroblasts. Clustering of individual samples is 11 
shown on top with the DIGE gel number and type of dye labeling for each sample listed 12 
at the bottom. Clustering of individual proteins is shown on the left with relative 13 
expression values displayed as an expression matrix (heat map) using a standardized log 14 
abundance scale ranging from negative values (green) to positive values (red), and the 15 
spot numbers are listed along the right side. These numbers are in agreement with those 16 
listed in Table 1. ↑P and ↓P, proteins whose expression is up- and down-regulated, 17 
respectively. 18 
Figure 5. DIGE assay validation. (A) Western-blot analysis of differentially-expressed 19 
proteins in BCS1L mutant fibroblasts. 10 µg of whole cell protein lysates were separated 20 
on 10% SDS-PAGE gels, blotted into nitrocellulose membranes and incubated with the 21 
indicated antibodies. (B) Quantitative changes in band intensities were evaluated by 22 
densitometric scanning with the Image J software. Signals from at least three 23 
independent experiments per sample were quantified; the densitometric mean values of 24 
the patients´ fibroblasts (n=4) were normalized to those of the loading control β-actin, 25 
and expressed as percentages of the mean control values (n=4, horizontal bar) ± 26 
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standard deviation. (a.d.u.), arbitrary densitometric units. (C) For the detection of the 1 
indicated proteins, indirect immunofluorescence was performed at least in duplicate per 2 
sample in fixed controls (n=3) and patients´ fibroblasts (n=4). A representative image is 3 
shown. 4 
Figure 6. Physiological validation of putative functional adaptations of human 5 
fibroblasts to mitochondrial respiratory chain complex III enzyme deficiency. 6 
Glycolysis up-regulation was assessed by enzymatic measurements of (A) cytosolic 7 
GAPDH and (B) mitochondrial PDH activities in the BCS1L mutant fibroblasts (n=4) 8 
and controls (n=4). Data are expressed as the mean values of three independent 9 
measurements per sample ± standard deviation. (a.d.u.), arbitrary densitometric units. 10 
 (C) Amino acids concentrations of serum-free cell culture media from control and 11 
BCS1L mutant fibroblasts. To determine the amino acids concentrations, cationic 12 
exchange chromatography was performed in triplicate per sample. Data are expressed as 13 
the mean values obtained from controls (n=4) and from the four patients´ fibroblasts ± 14 
standard deviation. 15 
Figure 7. Hypothetical model of the functional adaptations of human fibroblasts to 16 
mitochondrial respiratory chain complex III enzyme deficiency. Mutations in the 17 
BCS1L assembly factor cause severe complex III enzyme deficiency, which hampers 18 
oxygen consumption and ATP synthesis. A metabolic switch towards glycolysis and 19 
protein catabolism probably occurs in an attempt to maintain the intracellular ATP 20 
levels, increasing the ATP productive phase of glycolysis (1, 2 and 3) and decreasing 21 
the pyruvate dehydrogenase and Krebs cycle activities (4, 5). These events would lead 22 
to the accumulation of intermediate metabolites and amino acids (5, 6). A blockage of 23 
the pentose phosphate pathway (7, 8) could also be inferred, which would affect the 24 
synthesis of purines and pyrimidines and therefore nucleic / ribonucleic acids formation, 25 
resulting in an increased AMP/ATP ratio (9, 10). The detoxifying glutathione 26 
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metabolism would also be affected, which would amplify ROS damage (11). 1 
Eventually, the degradation of extracellular matrix components could take place as an 2 
alternative way to obtain energy (12), as well as alterations in the iron homeostasis (13) 3 
and the breakdown of the cytoskeleton architecture (14). These events could lead to 4 
alterations in the regulation of gene expression (15, 16 and 17), in intracellular 5 
trafficking and signal transduction mechanisms (18), as well as provoke a raise in the 6 
cellular responses to the oxidative and metabolic stress (19). Proteins whose levels were 7 
increased in the BCS1L mutant fibroblasts compared to the controls are indicated in red, 8 
and those whose levels were decreased are shown in green. Abbreviations are in 9 
accordance with the gene identity of proteins listed in Table 1. 10 
 11 
 12 
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Table 1. Proteins identified by 2-D DIGE-MS as differentially expressed in complex III-deficient fibroblasts grouped according to 
their predicted biological function. 
 
Spot 
No. 
Gene 
IDa 
Swiss-
Prota 
Protein name Av.ratiob t test Cellular role Loc.c Score d No.pept. /  
Number of mass 
valuese 
Cov. 
(%)f 
Metabolism 
3 MTHFD1 P11586 
 
C-1-tetrahydrofolate 
synthase 
 
-1.53 0.013 One-carbon 
metabolism; 
Tetrahydrofolate 
interconversion 
Cyt 176 25/65 31 
9 
mix 
H6PD O95479 Hexose-6-phosphate 
dehydrogenase 
-1.24 0.037 Pentose phosphate 
pathway 
Cyt / ER 62 
 
12/65 17 
17 ENO1 P06733 Alpha-enolase 1.3 0.03 Glycolisis Cyt 104 15/65 37 
23 
mix 
DLD P09622 Dihydrolipoyl 
dehydrogenase 
-1.35 0.036 Pyruvate 
decarboxylation; 
TCA cycle; 
Mitochondrial glycine 
cleavage system 
Mit 70 NLGLEELGIELDPR.G 
(46) 
7 
23 
mix 
G6PD P11413 Glucose-6-phosphate 
1-dehydrogenase 
-1.35 0.036 Pentose phosphate 
pathway 
Cyt 58 NSYVAGQYDDAASYQ
R.L (43) 
6 
25 DLST P36957 Dihydrolipoyl lysine-
residue 
succinyltransferase 
-1.63 0.019 TCA cycle Mit 154 16/34 31 
30 ALDOA P04075 Fructose-bisphosphate 
aldolase A 
-1.79 0.04 Glycolisis Cyt 144 17/65 59 
32 
mix 
GAPDH P04406 Glyceraldehyde-3-
phosphate 
dehydrogenase 
1.86 0.031 Glycolisis Cyt 122 17/59 50 
36 GNPDA1 P46926 Glucosamine-6-
phosphate isomerase 1 
1.51 0.012 Aminosugars 
metabolism 
Cyt 82 12/51 38 
39 
mix 
PGLS O95336 6-phospho 
gluconolactonase 
1.55 0.0064 Pentose phosphate 
pathway 
Cyt 133 WTLGFCDER.L (9) 
LLTVPFEKHSTL.- (29) 
IVAPISDSPKPPPQR.V 
(37) 
36 
43 APRT P07741 Adenine 
phosphoribosyl 
transferase 
1.33 0.037 AMP formation via 
purine ribonucleoside 
salvage 
Cyt 99 9/39 57 
45 FTL P02792 Ferritin light chain 2.2 0.021 Iron homeostasis Cyt 82 9/31 46 
Regulation of Gene Expression 
2 
mix 
SND1 Q7KZF4 Staphylococcal 
nuclease domain-
containing protein 1 
-1.32 0.036 Transcriptional 
coactivator 
Nuc  187 
 
26/65 32 
9 
mix 
DDX1 Q92499 ATP-dependent RNA 
helicase DDX1 
-1.24 0.037 Transcriptional 
coactivator; 
Nuc 207 
 
28/65 45 
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mRNA processing 
13 XRCC6 P12956 X-ray repair cross-
complementing protein 
6 
-1.48 0.018 Involved in DNA non-
homologous end 
joining, required for 
double-strand break 
repair and DNA 
somatic recombination 
Nuc 72 13/65 24 
14 XRCC6 P12956 X-ray repair cross-
complementing protein 
6 
-2.11 0.0034 Involved in DNA non-
homologous end 
joining, required for 
double-strand break 
repair and DNA 
somatic recombination 
Nuc 106 13/32 23 
18 SYNCRIP O60506 Heterogeneous nuclear 
ribonucleoprotein Q 
(hnRNP Q) 
1.26 0.024 mRNA processing and 
stability mechanisms 
Nuc 168 23/56 33 
19 LMNA P02545 
 
Lamin-A/C -1.65 0.028 Nuclear lamina 
component;  
Involved in nuclear 
membrane 
architecture, 
chromatin 
organization, and 
telomere dynamics 
Nuc 158 TALINSTGEEVAMR.K 
(13) 
VAVEEVDEEGKFVR.L 
(70) 
NSNLVGAAHEELQQSR
.I (43) 
15 
21 
mix 
NARS O43776 Asparagine-tRNA 
ligase 
2.18 0.0067 tRNA aminoacylation 
for protein translation 
Cyt 80 13/65 29 
31 EIF3H O15372 Eukaryotic translation 
initiation factor 3 
subunit H 
-1.22 0.017 Protein synthesis Cyt 76 LFKPPQPPAR.M (6) 
GEPPLPEEDLSK.L (25) 
QSRGEPPLPEEDLSK.L 
(20) 
12 
42 ABHD14B  Q96IU4 Alpha/beta hydrolase 
domain-containing 
protein 14B 
1.35 0.035 Putative 
transcriptional 
activator 
Nuc 68 6/17 34 
52 
mix 
SSBP1 Q04837 Mitochondrial single-
stranded DNA-binding 
protein (mtSSB) 
3.83 0.047 Mitochondrial DNA 
replication 
Mit 93 12/65 61 
Cytoskeleton formation and maintenance 
1 
 
VCL P18206 
 
Vinculin 
 
-1.42 
 
0.041 
 
Actin cytoskeleton; 
Cell-matrix and cell-
cell adhesion 
Cyt / PM 264 42/65 37 
4 GSN P06396 Gelsolin 2.97 0.017 Assembly / 
disassembly of actin 
filaments 
Cyt 73 13/65 18 
5 GSN P06396 Gelsolin 1.95 0.023 Assembly / 
disassembly of actin 
filaments 
Cyt  106 17/65 24 
6 GSN P06396 Gelsolin 1.92 0.032 Assembly / 
disassembly of actin 
Cyt 77 12/48 16 
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filaments 
8 GSN P06396 Gelsolin 3.39 0.042 Assembly / 
disassembly of actin 
filaments 
Cyt 61 12/60 17 
10 MSN P26038 Moesin -1.47 0.032 Connections between 
plasma membranes 
and actin-based 
cytoskeletons 
Cyt / PM 158 26/53 31 
11 MSN P26038 Moesin -1.52 0.011 Connections between 
plasma membranes 
and actin-based 
cytoskeletons 
Cyt / PM 116 25/65 30 
20 WDR1 O75083 WD-repeat containing 
protein 1 
-1.54 0.014 Disassembly of actin 
filaments  
Cyt 103 9/15 16 
21 
mix 
DPYSL2 Q16555 Dihydropyrimidinase-
related protein 2  
(CRMP-2) 
2.18 0.0067 Cytoskeleton 
remodeling 
Cyt 83 
 
13/65 35 
22 DPYSL2 Q16555 Dihydropyrimidinase-
related protein 2 
(CRMP-2) 
2.92 0.037 Cytoskeleton 
remodeling 
Cyt 189 25/65 52 
24 
mix 
VIM P08670 Vimentin -1.33 0.03 Intermediate filaments 
component 
Cyt 238 26/65 58 
24 
mix 
TUBA1B P68363 Tubulin alpha-1B chain -1.33 0.03 Microtubules 
constituent 
Cyt 197 22/65 50 
26 ARHGAP1 Q07960 Rho GTPase-activating 
protein 1  
(p50RhoGAP / 
CDC42GAP) 
1.2 0.028 Rho protein mediated 
signal transduction; 
Actin cytoskeleton 
remodeling 
Cyt / PM 108 15/65 33 
27 SEPT11 Q9NVA2 Septin-11 1.39 0.029 Filament-forming 
cytoskeletal GTPase 
Cyt  200 21/45 38 
Intracellular trafficking and signal transduction 
2 
mix 
SEC24D O94855 Protein transport 
protein SEC24D 
-1.32 0.036 Anterograde protein 
transport from ER to 
Golgi 
Cyt 67 
 
18/65 17 
28 SNX6 Q9UNH7 Sorting nexin-6 1.2 0.036 Retrograde protein 
transport from 
endosomes to the 
trans-Golgi network 
Cyt 191 25/65 50 
32 
mix 
ANXA2 P07355 Annexin A2 1.86 0.031 Endosomes sorting Cyt / ECM  153 19/59 53 
34 ANXA2 P07355 Annexin A2 2.06 0.044 Endosomes sorting Cyt / ECM 211 20/35 45 
37 ANXA4 P09525 Annexin A4 1.71 0.041 NF-kappaB signaling 
pathway; 
Possibly involved in 
exocytosis 
Cyt 366 39/65 73 
44 PEBP1 P30086 Phosphatidyl 
ethanolamine-binding 
protein 1  
1.2 0.033 Serine protease 
inhibitor; 
 Inhibits MAP kinase 
Cyt 158 14/65 64 
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(PEBP1 / RKIP) cascade 
52 
mix 
PEBP1 P30086 
 
Phosphatidyl 
ethanolamine-binding 
protein 1 
(PEBP1 / RKIP) 
3.83 0.047 Serine protease 
inhibitor;  
Inhibits MAP kinase 
cascade 
Cyt 90 9/65 54 
Cellular stress responses 
15 
mix 
PDIA4 P13667 Protein disulfide-
isomerase A4 
(ERP70) 
1.67 0.05 Processing and 
folding of secretory 
proteins in the ER 
ER 67 13/65 19 
15 
mix 
HSPA5 P11021 78 kDa glucose-
regulated protein 
(GRP78) 
1.67 0.05 Unfolded protein 
response;  
Required for ER 
integrity and stress-
induced autophagy 
ER 309 35/65 
 
47 
16 HSPA5 P11021 78 kDa glucose-
regulated protein 
(GRP78) 
2.03 0.034 Unfolded protein 
response;  
Required for ER 
integrity and stress-
induced autophagy 
ER 418 41/65 
 
55 
39 
mix 
ERP29 P30040 Endoplasmic reticulum 
resident protein 29 
(ERP29) 
1.55 0.0064 Processing and 
folding of secretory 
proteins in the ER 
ER 64 ILDQGEDFPASEMTR.I 
(31) 
26 
41 PARK7 Q99497 DJ-1 1.54 0.003 Redox sensor; 
Protects cells against 
oxidative stress; 
Transcriptional 
regulator; 
Maintenance of 
mitochondrial network 
morphology and 
mitophagy 
Cyt / Mit / 
Nuc 
86 10/21 43 
 
Cyt, cytoplasmic; Nuc, nuclear; ER, endoplasmic reticulum; Mit, mitochondrial; ECM, extracellular matrix; PM, plasma membrane. 
The first column (No.) indicates the protein spot numbers according to Fig. 3. Each spot was common to the total number (12) of gel images obtained in this analysis. 
a Gene and protein identities and accession numbers according to GenBank and Uniprot/Swiss-Prot/TrEMBL databases, respectively. 
b Average volume ratio OA/N quantified by DeCyder BVA module. 
c Subcellular localization according to Uniprot database and PSORT information. 
d Mascot MS protein score, or MS/MS ion score, obtained from MALDI-TOF/TOF spectra. In all cases, a probability score <0.01 was obtained. 
e Number of peptide masses matching the top hit from MS-Fit PMF / Number of peptide masses searched. On each spot, the 65 most intense peaks were launched for 
search. When peptide sequence appears, the fragmentation ions score is indicated between brackets. 
f Amino acid sequence coverage for the identified proteins. 
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